Arvinas Revenue and Competitors

License our Company Data API

#5707

Growjo Ranking

Estimated Revenue & Valuation

Arvinas's estimated annual revenue is currently $22.6M per year.(i)
Arvinas received $55.0M in venture funding in April 2018.
Arvinas's estimated revenue per employee is $42,067
Arvinas's total funding is $100M.
Arvinas's current valuation is $3.6B. (January 2022)

Employee Data

Arvinas has 537 Employees.(i)
Arvinas grew their employee count by 9% last year.

Arvinas's People

Name	Title	Email/Phone
1 Noah Berkowitz	Chief Medical Officer	Reveal Email/Phone
2 Diana Alicea	Executive Assistant To President & CEO	Reveal Email/Phone
3 John Houston	Chairperson, CEO, and President	Reveal Email/Phone
4 David Loomis	VP & Chief Accounting Officer	Reveal Email/Phone
5 Christina Sheil	VP Pharmacovigilance	Reveal Email/Phone
6 Janet Wang	VP, Head Translational Sciences, Oncology	Reveal Email/Phone
7 James Kirwin	Head Global Clinical Operations	Reveal Email/Phone
8 Sharvari Apte	VP Global and U.S. Commercial Analytics	Reveal Email/Phone
9 Charlie Romano	VP, Global Development Operations	Reveal Email/Phone
10 Janice Kapty	VP, Estrogen Receptor Global Asset Lead	Reveal Email/Phone

Arvinas Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 MontRidge	$0.2M	1	-80%	N/A	N/A
#2 Holiday Hill Da...	$4.3M	28	8%	N/A	N/A
#3 Bioxcel Corpora...	$9.8M	66	-11%	N/A	N/A
#4 Design Technolo...	$1.4M	9	350%	N/A	N/A
#5 Detect	$16.6M	107	-23%	N/A	N/A
#6 Trevi Therapeut...	$4.5M	29	-22%	N/A	N/A
#7 Enrich Therapeu...	$1.7M	11	57%	N/A	N/A
#8 Simcha Therapeu...	$2.3M	15	-6%	N/A	N/A
#9 Thetis Pharmace...	$0.3M	4	-43%	N/A	N/A
#10 East Granby Fam...	$4M	26	0%	N/A	N/A

Add Company

Show More Biotech Companies

What Is Arvinas?

Arvinas is a pharmaceutical company focused on developing new small molecules - known as PROTACs (PROteolysis TArgeting Chimeras) - aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting undruggable as well as druggable elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

$100M

Total Funding

537

Number of Employees

$22.6M

Revenue (est)

Employee Growth %

$3.6B

Valuation

N/A

Accelerator

Arvinas News

2022-04-19 - Arvinas, Inc. (NASDAQ:ARVN) Expected to Post Quarterly Sales of $29.11 Million

On average, analysts expect that Arvinas will report full year sales of $131.08 million for the current financial year, with estimates ranging...

2022-04-17 - Zacks: Analysts Expect Arvinas, Inc. (NASDAQ:ARVN) Will ...

Zacks: Analysts Expect Arvinas, Inc. (NASDAQ:ARVN) Will Announce Quarterly Sales of $29.11 Million. Posted by admin on Apr 22nd, 2022.

2022-04-17 - Zacks: Brokerages Expect Arvinas, Inc. (NASDAQ:ARVN) Will ...

Arvinas reported earnings of ($0.84) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of...

2019-09-08 - Arvinas To Present at the Wedbush PacGrow Healthcare ...

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) — Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of ...

Other Companies in New Haven

Company Name	Revenue	Number of Employees	Employee Growth	Total Funding
#1 The United Illu...	$154.8M	563	3%	N/A
#2 New Haven Board...	$151.7M	592	3%	N/A
#3 Cornell Scott -...	$206.9M	613	6%	N/A
#4 Hopkins School	$144.9M	644	N/A	N/A
#5 Iran Human Righ...	$15M	750	-1%	N/A